Expert Interview
Evaluating Merck's data for enlicitide decanoate (Oral PCSK9 Inhibitor) in lowering LDL-C versus existing non-statin therapies
Ticker(s): MRK, AMGN, SNY, REGN, PFE, AZNInstitution: Utah Lipid Center
- President and Director of the Utah Lipid Center and past president of the American Board of Clinical Lipidology.
- Treats 50 patients with hypertriglyceridemia (SHTG)
- Responsible for writing guidelines for the American Heart Association and the American Association of Clinical Endocrinology; has co-authored over 160 scientific articles, reviews, book chapters.
How do you view the current treatment landscape for lowering LDL-C in patients who are not adequately controlled on statins?
Added By: dami_adminHow do you view the current treatment landscape for lowering LDL-C in patients who are not adequately controlled on statins?
Added By: dami_adminWhat is your level of excitement for enlicitide decanoate?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
